NCT02538614 2020-11-25
Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 1 Terminated
Clinical Trials
4 trialsNCT02759016 2020-09-29
Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib
Boehringer Ingelheim
Phase 1 Completed
NCT01296932 2020-08-20
BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)
Boehringer Ingelheim
Phase 1 Completed
NCT03343678 2018-01-09
This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax
Boehringer Ingelheim
Phase 1 Withdrawn